Details

Autor(en) / Beteiligte

• Palich, R.
• Veyri, M.
• Marot, S.
• Vozy, A.
• Gligorov, J.
• Maingon, P.
• Marcelin, A.-G.
• Spano, J.-P.

Titel

Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients

Ist Teil von

• Annals of oncology, 2021-08, Vol.32 (8), p.1051-1053

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2021

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Active cancer and ongoing antineoplastic treatments are major factors for severe COVID-19 and death, reasons why the SARS-CoV-2 vaccination remains a priority in cancer patients (CPs). However, immunocompromised patients were excluded from major studies on mRNA vaccines, and could have a decreased response to vaccination, as recently demonstrated in solid organ transplant recipients. Herein, we aimed to assess the proportion of antibody response 4 weeks after the first injection of the BNT162b2 (Pfizer-BioNTech) vaccine in CPs and health care workers (HCWs) as the control population.